M1 Kliniken AG: Strong Q1 2025 with 29% EBIT Growth and Earnings per Share of EUR 0.31

EQS-News: M1 Kliniken AG / Key word(s): Quarter Results/Quarterly / Interim Statement M1 Kliniken AG: Strong Q1 2025 with 29% EBIT Growth and Earnings per Share of EUR 0.31 05.06.2025 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. M1 Kliniken AG: Strong Q1 2025 with 29% EBIT Growth and Earnings per Share of EUR 0.31

Berlin, 5 June 2025 – M1 Kliniken AG (ISIN: DE000A0STSQ8) has made a strong start to the 2025 financial year and continues its profitable growth trajectory. The significant improvement in earnings results from the consistent implementation of efficiency measures and the targeted expansion of medical capacities.

Key Financials at a Glance

• Group revenue: +9.5% to EUR 92.7 million (Q1 2024: EUR 84.7 million)
• EBITDA: +22% to EUR 10.0 million (Q1 2024: EUR 8.2 million)
• EBIT: +29% to EUR 8.8 million (Q1 2024: EUR 6.8 million)
• EBIT margin: 9.5% (Q1 2024: 8.1%)
• EBT: +23% to EUR 8.6 million (Q1 2024: EUR 7.0 million)
• Earnings per share: EUR 0.31 (Q1 2024: EUR 0.26)

Beauty Segment: Profitability Further Increased

• Revenue: +3.6% to EUR 25.6 million (Q1 2024: EUR 24.7 million)
• EBIT: +24% to EUR 6.7 million (Q1 2024: EUR 5.4 million)
• EBIT margin: 26% (Q1 2024: 21.9%)

The Beauty segment remains the Group’s main earnings driver. In Q1, it benefited in particular from efficiency gains through optimized processes and higher utilization of medical capacity. A targeted pricing strategy helped attract new customer groups and support market share expansion, without impacting margin quality. M1 continues to pursue its positioning as a leading provider of high-quality aesthetic medicine at market-leading prices.

Trading Segment: Double-Digit Growth in Revenue and EBIT

• Revenue: +12% to EUR 67.2 million (Q1 2024: EUR 60.0 million)
• EBIT: +50% to EUR 2.1 million (Q1 2024: EUR 1.4 million)

The trading segment continued its positive development in Q1, once again posting double-digit growth in both revenue and EBIT. Segment profitability was further improved.